- Home
- CLFD vs KROS Comparison
CLFD vs KROS Comparison
Compare CLFD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLFD
- KROS
- Stock Information
- Founded
- CLFD 1979
- KROS 2015
- Country
- CLFD United States
- KROS United States
- Employees
- CLFD N/A
- KROS N/A
- Industry
- CLFD Telecommunications Equipment
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CLFD Utilities
- KROS Health Care
- Exchange
- CLFD Nasdaq
- KROS Nasdaq
- Market Cap
- CLFD 494.4M
- KROS 565.0M
- IPO Year
- CLFD N/A
- KROS 2020
- Fundamental
- Price
- CLFD $35.92
- KROS $15.96
- Analyst Decision
- CLFD Strong Buy
- KROS Buy
- Analyst Count
- CLFD 1
- KROS 14
- Target Price
- CLFD $50.00
- KROS $20.56
- AVG Volume (30 Days)
- CLFD 108.1K
- KROS 387.5K
- Earning Date
- CLFD 11-06-2025
- KROS 11-05-2025
- Dividend Yield
- CLFD N/A
- KROS N/A
- EPS Growth
- CLFD N/A
- KROS N/A
- EPS
- CLFD 0.01
- KROS 0.47
- Revenue
- CLFD $179,319,000.00
- KROS $232,844,000.00
- Revenue This Year
- CLFD $11.41
- KROS $6,657.47
- Revenue Next Year
- CLFD $13.55
- KROS N/A
- P/E Ratio
- CLFD $2,514.92
- KROS $34.29
- Revenue Growth
- CLFD 5.72
- KROS 85820.30
- 52 Week Low
- CLFD $23.78
- KROS $9.12
- 52 Week High
- CLFD $46.76
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CLFD 54.19
- KROS 53.30
- Support Level
- CLFD $33.30
- KROS $15.50
- Resistance Level
- CLFD $36.55
- KROS $16.57
- Average True Range (ATR)
- CLFD 0.90
- KROS 0.53
- MACD
- CLFD 0.33
- KROS -0.05
- Stochastic Oscillator
- CLFD 58.40
- KROS 48.41
About CLFD Clearfield Inc.
Clearfield Inc mainly designs, manufactures, and distributes fiber protection, fiber management and fiber delivery solutions for communications networks. It provides a various products including copper assemblies, cassettes, box enclosures, fiber connectors, frames, microduct, terminals, vaults, pedestal inserts, FieldSmart, WaveSmart, and CraftSmart. The company has international presence with the majority of the revenue derived from the United States. The company has two reportable segments namely Clearfield segment and Nestor cables segment. The majority of revenue is derived from Clearfield segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.